Lawrence Eichenfield, MD

Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.

A review of topical therapies that have been long utilized for patients with atopic dermatitis.

A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.

Expert insight on nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.

A brief evaluation of the concomitant use of JAK inhibitors, topical or systemic, in patients with atopic dermatitis.

Switching its focus to systemic JAK inhibitors, the panel reviews real-world use of available agents to treat patients with atopic dermatitis.

The panelists discuss real-world use of topical ruxolitinib in atopic dermatitis management given safety, efficacy, and availability.

Considerations for topical ruxolitinib with deference to positive clinical trial results in atopic dermatitis.

Shared insight on the available JAK inhibitors for atopic dermatitis, both topical and systemic.

Experts reflect on the various comorbid conditions associated with atopic dermatitis and how they can affect patients.

Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.

Considerations for persistent atopic dermatitis vs outgrowing disease, followed by triggers that can result in flare-ups.

Shared insight on the ways a child or adult may present with atopic dermatitis.

A panel of experts review the pathophysiology of atopic dermatitis and its contributing factors.